Emerging molecular markers for the prognosis of differentiated thyroid cancer patients

International Journal of Surgery

Volumn 12, Issue , 2014, Pages S52-S56

  Baldini, Enke ^a   Sorrenti, Salvatore ^a   Tuccilli, Chiara ^a   Prinzi, Natalie ^a   Coccaro, Carmela ^a   Catania, Antonio ^a   Filippini, Angelo ^a   Bononi, Marco ^a   De Antoni, Enrico ^a   D'Armiento, Massimino ^a   Ulisse, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BRAF; Estrogen receptor; MiRNA; Prognosis; Thyroid cancer; TNM; Urokinase plasminogen activating systeml

Indexed keywords

MICRORNA; PLASMINOGEN; THYROGLOBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MOLECULAR MARKER; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; DIFFERENTIATED THYROID CANCER; DISEASE FREE INTERVAL; HUMAN; MALIGNANT TRANSFORMATION; PRACTICE GUIDELINE; PREDICTION; PREDICTIVE VALUE; SURVIVAL TIME; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; THYROID CELL; WHOLE BODY SCINTISCANNING; AGE DISTRIBUTION; APOPTOSIS; CANCER RECURRENCE; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; GENOMIC INSTABILITY; HIGH RISK POPULATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; ANAPLASTIC THYROID CANCER; CANCER PATIENT; CANCER SIZE; CELL FUNCTION; CHROMOSOME ABERRATION; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; EXTRACELLULAR MATRIX; LYMPH NODE METASTASIS; OVERALL SURVIVAL; POORLY DIFFERENTIATED THYROID CANCER; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA, FOLLICULAR; CARCINOMA; METABOLISM; PROGNOSIS; THYROID NEOPLASMS;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA; HUMANS; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84930658792     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2014.05.054     Document Type: Article

References (97)

1. S.I. Sherman, Thyroid carcinoma, Lancet 361 (2003) 501-511.
2. A. Jemal, R. Siegel, E. Ward, et al., Cancer statistics, 2009, CA Cancer J. Clin. 59 (2009) 225-249.
3. P. Trimboli, S. Ulisse, F.M. Graziano, et al., Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years, Thyroid 16 (2006) 1151-1155.
4. L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973-2002, JAMA 295 (2006) 2164-2167.
5. B.K. Kinder, Well differentiated thyroid cancer, Curr. Opin. Oncol. 15 (2003) 71-77.
6. J.L. Pasieka, Anaplastic thyroid cancer, Curr. Opin. Oncol. 15 (2003) 78-83.
7. R. Paschke, L. Hegedüs, E. Alexander, R. Valcavi, E. Papini, H. Gharib, Thyroid nodule guidelines: agreement, disagreement and need for future research, Nat. Rev. Endocrinol. 7 (2011) 354-361.
8. S.A. Roman, Endocrine tumors: evaluation of the thyroid nodule, Curr. Opin. Oncol. 15 (2003) 66-70.
9. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer D.S. Cooper, G.M. Doherty, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid 19 (2009) 1167-1214.
10. D. Hanahan, R.A. Weimberg, The hallmark of cancer, Cell 100 (2000) 57-70.
11. Y.E. Nikiforov, Diagnostic Pathology and Molecular Genetics of the Thyroid, Lippincott Williams & Wilkins, Philadelphia, 2009.
12. Y.E. Nikiforov, M.N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer, Nat. Rev. Endocrinol. 7 (2011) 569-580.
13. B. Shahedian, Y. Shi, M. Zou, N.R. Farid, Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations, Mol. Genet. Metab. 72 (2001) 155-163.
14. V.B. Wressmann, R.A. Ghossein, S.G. Patel, et al., Genome-wide appraisal of thyroid cancer progression, Am. J. Pathol. 161 (2002) 1549-1556.
15. K.N. Patel, A.R. Shaha, Poorly differentiated and anaplastic thyroid cancer, Cancer Control 13 (2006) 119-128.
16. J.A. Fagin, Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid, Mol. Endocrinol. 16 (2002) 903-911.
17. B. Ouyang, J.A. Knauf, K. Ain, B. Nacev, J.A. Fagin, Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1, Clin. Endocrinol. 56 (2002) 341-350.
18. Y. Ito, E. Miyoshi, N. Sasaki, et al., Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma, Br. J. Cancer 90 (2004) 414-418.
19. S. Ulisse, J.G. Delcros, E. Baldini, et al., Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues, Int. J. Cancer 119 (2006) 275-282.
20. S. Ulisse, J.G. Delcros, E. Baldini, et al., Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues, Endocr. Relat. Cancer 14 (2007) 831-842.
21. M.A. Huber, N. Kraut, H. Beug, Molecular requirements for epithelialmesenchymal transition during tumor progression, Curr. Opin. Cell Biol. 17 (2005) 548-558.
22. V. Vasko, A.V. Espinosa, W. Scouten, et al., Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2803-2808.
23. M. Schlumberger, G. Berg, O. Cohen, et al., Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective, Eur. J. Endocrinol. 150 (2004) 105-112.
24. F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur. J. Endocrinol. 154 (2006) 787-803.
25. C.F. Eustatia-Rutten, E.P. Corssmit, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.W. Smit, Survival and death causes in differentiated thyroid carcinoma, J. Clin. Endocrinol. Metab. 91 (2006) 313-319.
26. M.K. Gospodarowicz, D.E. Henson, R.V.P. Hutter, B. O'Sullivan, L.H. Sobin, C.L. Wittekind, Prognostic Factors in cancer, second ed., Wiley-Liss, New York, 2001.
27. C. Passler, C. Scheuba, G. Prager, et al., Prognostic factors of papillary and follicular thyroid cancers: differences in an iodine-replete endemic goiter region, Endocr. Relat. Cancer 11 (2004) 131-139.
28. [2009] AJCC Cancer Staging Manual, seventh ed., Springer-Verlag, New York, 2009.
29. F. Pacini, M.G. Castagna, L. Brilli, G. Pentheroudakis, on behalf of the ESMO Guidelines Working Group, Thyroid cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up, Ann. Oncol. 23 (2012) 110-119.
30. M.G. Castagna, F. Maino, C. Cipri, et al., Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur. J. Endocrinol. 165 (2011) 441-446.
31. D. Handkiewicz-Junak, A. Czarniecka, B. Jarząb, Molecular prognostic markers in papillary thyroid cancer: current status and future directions, Mol. Cell. Endocrinol. 322 (2010) 8-28.
32. D. Shibru, K.W. Chung, E. Kebebew, Recent developments in the clinical application of thyroid cancer biomarkers, Curr. Opin. Oncol. 20 (2008) 13-18.
33. M. Xing, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications, Endocr. Rev. 28 (2007) 742-762.
34. S. Ulisse, E. Baldini, S. Sorrenti, et al., In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval, Clin. Endocrinol. 77 (2012) 780-786.
35. A. Guerra, M.R. Sapio, V. Marotta, et al., The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma, J. Clin. Endocrinol. Metab. 97 (2012) 517-524.
36. Y. Ito, H. Yoshida, R. Maruo, et al., BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients, Endocr. J. 56 (2009) 89-97.
37. X. Zheng, S. Wei, Y. Han, et al., Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases, Ann. Surg. Oncol. 20 (2013) 2266-2273.
38. S. Ulisse, E. Baldini, S. Sorrenti, M. D'Armiento, The urokinase plasminogen activator system: a target for anti-cancer therapy, Curr. Cancer Drug Targets 9 (2009) 32-71.
39. M.J. Duffy, The urokinase plasminogen activator system: role in malignancy, Curr. Pharm. Des. 10 (2004) 39-49.
40. F. Jänicke, A. Prechtl, C. Thomssen, et al., Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J. Natl. Cancer Inst. 93 (2001) 913-920.
41. M.J. Duffy, Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancer, Biochem. Soc. Trans. 30 (2002) 207-210.
42. M. Schmitt, N. Harbeck, C. Thomssen, et al., Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy, Thromb. Haemost. 78 (1997) 285-296.
43. M.P. Look, W.L. van Putten, M.J. Duffy, et al., Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients, J. Natl. Cancer Inst. 94 (2002) 116-128.
44. J.A. Foekens, H.A. Peters, M.P. Look, et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, Cancer Res. 60 (2000) 636-643.
45. L. Harris, H. Fritsche, R. Mennel, et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J. Clin. Oncol. 25 (2007) 5287-5312.
46. J.D. Ramsden, S. Yarram, E. Mathews, J.C. Watkinson, M.C. Eggo, Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen, J. Endocrinol. 173 (2002) 475-481.
47. P. Ragno, N. Montuori, S. Salzano, G. Rossi, Urokinase-type plasminogenactivator and normal thyroid cell adhesion to the extracellular matrix, Biochimie 81 (1999) 355-358.
48. N. Montuori, G. Rossi, P. Ragno, Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells, FEBS Lett. 460 (1999) 32-36.
49. N. Montuori, S. Salzano, G. Rossi, P. Ragno, Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor, FEBS Lett. 476 (2000) 166-170.
50. Y. Ito, T. Takeda, T. Kobayashi, et al., Plasminogen activation system is active even in thyroid tumors; an immunohistochemical study, Anticancer Res. 16 (1996) 81-89.
51. K.S. Packman, M.J. Demeure, K.M. Doffek, S.D. Wilson, Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells, Surgery 118 (1995) 1011-1016.
52. S.J. Kim, E. Shiba, T. Taguchi, et al., uPA receptor expression in benign and malignant thyroid tumors, Anticancer Res. 22 (2002) 387-393.
53. A. Zanetti, A. Stoppacciaro, A. Marzullo, et al., Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid, J. Pathol. 186 (1998) 287-291.
54. J.W. Smith, G. van der Pluijm, H.A. Romijn, C.W. Lowik, H. Morreau, B.M. Goslings, Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system, Thyroid 9 (1999) 913-919.
55. S. Ulisse, E. Baldini, M. Toller, et al., Differential expression of the components of the plasminogen activating system in human thyroid tumor derived cell lines and papillary carcinomas, Eur. J. Cancer 42 (2006) 2631-2638.
56. T.S. Nowicki, N.T. Kummer, C. Iacob, et al., Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells, Laryngoscope 120 (2010) 1383-1390.
57. T.S. Nowicki, H. Zhao, Z. Darzynkiewicz, et al., Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells, Cell Cycle 10 (2011) 100-107.
58. B. Sid, B. Langlois, H. Sartelet, G. Bellon, S. Dedieu, L. Martiny, Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity, Int. J. Biochem. Cell. Biol. 40 (2008) 1890-1900.
59. B. Sid, S. Dedieu, N. Delorme, et al., Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator, Int. J. Biochem. Cell. Biol. 38 (2006) 1729-1740.
60. Q.D. Chu, T.C. Hurd, S. Harvey, et al., Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis, Diagn. Mol. Pathol. 13 (2004) 241-246.
61. S. Ulisse, E. Baldini, S. Sorrenti, et al., High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma, J. Clin. Endocrinol. Metab. 96 (2011) 504-508.
62. D. Buergy, T. Weber, G.D. Maurer, G. Mudduluru, F. Medved, J.H. Leupold, et al., Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies, Int. J. Cancer 125 (2009) 894-901.
63. E. Baldini, S. Sorrenti, E. D'Armiento, F.M. Di Matteo, A. Catania, S. Ulisse, The urokinase plasminogen activating system in thyroid cancer: clinical implications, G. Chir. 33 (2012) 305-310.
64. G. Horvatić Herceg, D. Herceg, M. Kralik, Z. Bence-Zigman, H. Tomić-Brzac, A. Kulić, Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study, Wien. Klin. Wochenschr. 118 (2006) 601-609.
65. G. Horvatić Herceg, D. Herceg, M. Kralik, et al., Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients, Otolaryngol. Head Neck Surg. 149 (2013) 533-540.
66. J.D. Blaustein, Steroid hormone receptors: long- and short-term integrators of the internal milieu and the external environment, Horm. Metab. Res. 44 (2012) 563-568.
67. S. Mosselman, J. Polman, R. Dijkema, ER beta:identification and characterization of a novel human estrogen receptor, FEBS Lett. 392 (1996) 49-53.
68. G.G. Chen, Q. Zeng, G.M. Tse, Estrogen and its receptor in cancer, Med. Res. Rev. 28 (2008) 954-974.
69. F. Wu, R. Xu, K. Kim, J. Martin, S. Safe, In vivo profiling of estrogen receptor/ specificity protein-dependent transactivation, Endocrinology 149 (2008) 5696-5705.
70. S. Ali, R.C. Coombes, Estrogen receptor alpha in human breast cancer: occurrence and significance, J. Mammary Gland Biol. Neoplasia 5 (2000) 271-281.
71. A. Halon, E. Nowak-Markwitz, A. Maciejczyk, et al., Loss estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients, Anticancer Res. 31 (2011) 711-718.
72. H. Kawai, A. Ishii, K. Washiya, et al., Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer, Clin. Cancer Res. 11 (2000) 5084-5089.
73. Y. Omoto, S. Inoue, S. Ogawa, et al., Clinical value of wild-type estrogen receptor beta expression in breast cancer, Cancer Lett. 163 (2001) 207-212.
74. A. Halon, V. Materna, M. Drag-Zalesinska, et al., Estrogen receptor alpha expression in ovarian cancer predicts longer survival, Pathol. Oncol. Res. 17 (2011) 511-518.
75. L.V. Mauro, M. Dalurzo, M.J. Carlini, et al., Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer, Oncol. Rep. 24 (2010) 1331-1338.
76. A. de la Chapelle, K. Jazdzewski, MicroRNAs in thyroid cancer, J. Clin. Endocrinol. Metab. 96 (2011) 3326-3336.
77. Q. Zeng, G.G. Chen, A.C. Vlantis, C.A. van Hasselt, Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway, Cell Prolif. 40 (2007) 921-935.
78. S. Rajoria, R. Suriano, A. Shanmugam, et al., Metastatic phenotype is regulated by estrogen in thyroid cells, Thyroid 20 (2010) 33-41.
79. L. Dalla Valle, A. Ramina, S. Vianello, A. Fassina, P. Belvedere, L. Colombo, Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues, J. Clin. Endocrinol. Metab. 83 (1998) 3702-3709.
80. M. Di Vito, E. De Santis, G.A. Perrone, et al., Overexpression of estrogen receptor-a in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology, Cancer Sci. 102 (2011) 1921-1927.
81. S.H. Golden, A. Brown, J.A. Cauley, et al., Health disparities in endocrine disorders: biological, clinical, and nonclinical factors - an endocrine society statement, J. Clin. Endocrinol. Metab. 97 (2012) E1579-E1639.
82. M.L. Lee, G.G. Chen, A.C. Vlantis, G.M. Tse, B.C. Leung, C.A. van Hasselt, Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL, Cancer J. 11 (2005) 113-121.
83. A. Heikkilä, J. Hagström, H. Mäenpää, et al., Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome, Thyroid 23 (2013) 456-465.
84. D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004) 281-297.
85. D.P. Bartel, MicroRNAs: target recognition and regulatory functions, Cell 136 (2004) 215-233.
86. S.A.Melo,M. Esteller, Disruption ofmicroRNA nuclear transport in human cancer, Semin. Cancer Biol. (2014), http://dx.doi.org/10.1016/j.semcancer.2014.02.012.
87. H. Jiang, G. Zhang, J.H. Wu, C.P. Jiang, Diverse roles of miR-29 in cancer, Oncol. Rep. 31 (2014) 1509-1516.
88. J. Liu, W. Shi, C. Wu, J. Ju, J. Jiang, miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer, Biomed. Rep. 2 (2014) 7-11.
89. L. Lodewijk, A.M. Prins, J.W. Kist, et al., The value of miRNA in diagnosing thyroid cancer: a systematic review, Cancer Biomark. 11 (2012) 229-238.
90. M.N. Nikiforova, G.C. Tseng, S. Steward, D. Diorio, Y.E. Nikiforov, MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility, J. Clin. Endocrinol. Metab. 93 (2008) 1600-1608.
91. B. Woitas, C. Ferraz, T. Stokowy, et al., Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas, Mol. Cell. Endocrinol. 388 (2014) 1-9.
92. C.K. Chou, R.F. Chen, F.F. Chou, et al., miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation, Thyroid 20 (2010) 489-494.
93. B. Amato, R. Compagna, L. Sivero, V. Salvati, M. Amato, G. Vigliotti, A. Rocca, M. Donisi, Lymphectomy for elderly in thyroid surgery, Chirurgia 26 (4) (2013 Aug) 303-306.
94. G. Romano, E. Luna, G. Cocchiara, F. Calderone, C. Zumbino, M. Muzio, M.C. Lo Nigro, A.I. Lo Monte, G. Buscemi, C. Di Bernardo, N. Napoli, The surgical treatment of nodular thyroid lesions: our experience. Analysis of 462 cases, G. Chir. 25 (1-2) (2004 Jan-Feb) 23-26 (Review).
95. A. Sanguinetti, G. Docimo, M. Ragusa, F. Calzolari, F. D'Ajello, R. Ruggiero, D. Parmeggiani, A. Pezzolla, E. Procaccini, N. Avenia, Ultrasound scissors versus electrocautery in axillary dissection: our experience, G. Chir. 31 (4) (2010 Apr) 151-153. PubMed PMID: 20444331.
96. R. Gervasi, G. Orlando, M.A. Lerose, B. Amato, G. Docimo, P. Zeppa, A. Puzziello, Thyroid surgery in geriatric patients: a literature review, BMC Surg. 12 (Suppl. 1) (2012) S16, http://dx.doi.org/10.1186/1471-2482-12-S1-S16.
97. C.K. Chou, K.D. Yang, F.F. Chou, et al., Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma, J. Clin. Endocrinol. Metab. 98 (2013) E196-E205.